Recently, CAAR technology was repurposed to treat a blood disorder (hemophilia A) rather than an autoimmune disease by Parvathaneni et al. Hemophilia A is a hereditary bleeding disorder caused by a lack of coagulation factor FVIII in serum and is commonly treated by replacement FVIII therapy [182]. The gene discussed is F8; the disease is hemophilia A.